Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5 Released 03 Apr 23
Latest announcements
Announcement summary
Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5
Emyria Limited has entered into a binding Term Sheet (Agreement) with Aspen Pharmacare Australia (Aspen Australia) for the licensing and commercialisation of EMD-RX5.
Ask a question
Your question will be sent privately to Emyria. The company may choose to make this question public.
Investor Q&A's
Start the conversation
Ask Emyria a question about this announcement.